Back to Baker Bros. Advisors LP Baker Bros. Advisors LP

XENEXENE

Showing 8 of 25 quarters

Position history for Baker Bros. Advisors LPBaker Bros. Advisors LP's holdings in Xenon Pharmaceuticals Inc.

Yes. Baker Bros. Advisors holds 370,208 shares of XENE (Xenon Pharmaceuticals), worth $22.3M, as of its Q2 2026 13F filing. The share count is unchanged from Q1 2026. Baker Bros. Advisors has held XENE since Q2 2020, across 25 quarterly 13F filings. XENE is 0.1% of Baker Bros. Advisors' reported 13F portfolio.

Current Value

$22.3M

Current Shares

370,208

Total Value Change

-$16.8M

Total Shares Change

-623,471

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Unchanged
370,208
0.0%
$22.3M0.1%$60.36
0
2026-Q1
Unchanged
370,208
0.0%
$21.5M0.1%$43.79
0
2025-Q4
Unchanged
370,208
0.0%
$16.6M0.1%$44.12
0
2025-Q3
Unchanged
370,208
0.0%
$14.9M0.1%$39.06
0
2025-Q2
Increased
370,208
+6.6%
$11.6M0.1%$32.40
36
2025-Q1
Decreased
347,408
-65.0%
$11.7M0.1%$34.26
0
2024-Q4
Unchanged
993,679
0.0%
$39M0.4%$38.53
0
2024-Q3
Unchanged
993,679
0.0%
$39.1M0.4%$38.65
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used